NasdaqGS - Nasdaq Real Time Price USD

Repligen Corporation (RGEN)

149.09 +0.91 (+0.61%)
At close: May 31 at 4:00 PM EDT
149.09 0.00 (0.00%)
After hours: May 31 at 4:43 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
607,450.00
638,764.00
801,536.00
670,534.00
366,260.00
--
Cost of Revenue
348,468.00
353,922.00
345,830.00
279,280.00
156,634.00
--
Gross Profit
258,982.00
284,842.00
455,706.00
391,254.00
209,626.00
--
Operating Expense
264,735.00
260,835.00
259,765.00
218,140.00
139,803.00
--
Operating Income
-5,753.00
24,007.00
195,941.00
173,114.00
69,823.00
--
Net Non Operating Interest Income Expense
-14,673.00
-10,026.00
-2,977.00
-12,714.00
-12,133.00
--
Other Income Expense
50,580.00
50,151.00
26,176.00
-6,857.00
1,527.00
--
Pretax Income
30,154.00
64,132.00
219,140.00
153,543.00
59,217.00
--
Tax Provision
15,312.00
22,555.00
33,181.00
25,252.00
-709.00
--
Net Income Common Stockholders
14,842.00
41,577.00
185,959.00
128,291.00
59,926.00
--
Diluted NI Available to Com Stockholders
14,842.00
41,577.00
185,959.00
128,291.00
59,926.00
--
Basic EPS
0.27
0.75
3.35
2.33
1.14
--
Diluted EPS
0.27
0.74
3.24
2.24
1.11
--
Basic Average Shares
55,770.25
55,720.00
55,460.00
55,015.00
52,554.00
--
Diluted Average Shares
56,247.50
56,377.00
57,455.00
57,264.00
53,892.00
--
Total Operating Income as Reported
25,351.00
54,576.00
224,670.00
167,249.00
69,823.00
--
Total Expenses
613,203.00
614,757.00
605,595.00
497,420.00
296,437.00
--
Net Income from Continuing & Discontinued Operation
14,842.00
41,577.00
185,959.00
128,291.00
59,926.00
--
Normalized Income
-12,800.00
14,342.86
155,643.76
133,044.38
58,655.07
--
Interest Expense
6,572.00
1,951.00
1,162.00
11,278.00
10,768.00
--
Net Interest Income
-14,673.00
-10,026.00
-2,977.00
-12,714.00
-12,133.00
--
EBIT
36,726.00
66,083.00
220,302.00
164,821.00
69,985.00
--
EBITDA
106,350.00
134,168.00
271,287.00
203,268.00
97,052.00
--
Reconciled Cost of Revenue
348,468.00
353,922.00
345,830.00
279,280.00
156,634.00
--
Reconciled Depreciation
69,624.00
68,085.00
50,985.00
38,447.00
27,067.00
--
Net Income from Continuing Operation Net Minority Interest
14,842.00
41,577.00
185,959.00
128,291.00
59,926.00
--
Total Unusual Items Excluding Goodwill
46,070.00
42,028.00
35,707.00
-5,689.00
1,741.00
--
Total Unusual Items
46,070.00
42,028.00
35,707.00
-5,689.00
1,741.00
--
Normalized EBITDA
60,280.00
92,140.00
235,580.00
208,957.00
95,311.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
18,428.00
14,793.86
5,391.76
-935.62
470.07
--
12/31/2019 - 4/29/1986

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

HOLX Hologic, Inc.
73.78
+1.65%
 
ICUI ICU Medical, Inc.
106.34
+2.71%
 
TFX Teleflex Incorporated
209.07
+1.18%
 
WST West Pharmaceutical Services, Inc.
331.41
+0.70%
 
ATR AptarGroup, Inc.
147.69
+1.06%
 
HAE Haemonetics Corporation
84.08
-0.67%
 
STVN Stevanato Group S.p.A.
20.32
+3.83%
 
AZTA Azenta, Inc.
50.51
-0.86%
 
ANIK Anika Therapeutics, Inc.
25.65
-0.23%
 
LMAT LeMaitre Vascular, Inc.
78.88
+0.14%